Technical Analysis for CVAC - CureVac N.V.

Grade Last Price % Change Price Change
grade B 81.79 -0.38% -0.31
CVAC closed down 0.38 percent on Wednesday, November 25, 2020, on 64 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical CVAC trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Calm After Storm Range Contraction -0.38%
Multiple of Ten Bullish Other -0.38%
Wide Bands Range Expansion -0.38%
Overbought Stochastic Strength -0.38%
Calm After Storm Range Contraction -3.84%
Older End-of-Day Signals for CVAC ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 11 hours ago
Down 3% about 17 hours ago
Down 2 % about 17 hours ago
Down 1% about 17 hours ago
Gapped Down (Partial) about 17 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Biopharmaceutical Solid Tumors Health Care Vaccination Pharmaceutical Companies Rabies Arcturus Therapeutics Boehringer Ingelheim

Is CVAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 85.68
52 Week Low 36.15
Average Volume 475,695
200-Day Moving Average 0.00
50-Day Moving Average 56.35
20-Day Moving Average 65.35
10-Day Moving Average 78.55
Average True Range 5.14
ADX 32.52
+DI 40.00
-DI 18.54
Chandelier Exit (Long, 3 ATRs ) 70.27
Chandelier Exit (Short, 3 ATRs ) 61.53
Upper Bollinger Band 93.58
Lower Bollinger Band 37.12
Percent B (%b) 0.79
BandWidth 86.40
MACD Line 8.14
MACD Signal Line 6.36
MACD Histogram 1.7767
Fundamentals Value
Market Cap 14.56 Billion
Num Shares 178 Million
EPS
Price-to-Sales 646.43
Price-to-Book 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 86.01
Resistance 3 (R3) 85.61 83.82 85.30
Resistance 2 (R2) 83.82 82.74 84.01 85.07
Resistance 1 (R1) 82.80 82.08 81.91 83.20 84.83
Pivot Point 81.01 81.01 80.56 81.20 81.01
Support 1 (S1) 79.99 79.93 79.10 80.39 78.75
Support 2 (S2) 78.20 79.27 78.39 78.51
Support 3 (S3) 77.18 78.20 78.28
Support 4 (S4) 77.58